DBV Technologies vs TScan Therapeutics
DBVT and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DBVT and TCRX compare
DBV Technologies is the larger company, worth 288 times as much as TScan Therapeutics ($3.6B against $12.6M).
DBV Technologies grew revenue faster over the last twelve months (−31.6% versus −38.4% for TScan Therapeutics).
TScan Therapeutics keeps more of each dollar of sales as profit, with a net margin of −2219% compared with −5405% at DBV Technologies.
DBV Technologies scores higher on the StockData Score (6 against 4 for TScan Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DBVT | TCRX |
|---|---|---|
| Size and price | ||
| Market cap | $3.6B | $12.6M |
| Share price | $11.51 | $0.186 |
| Change, 1 year | −17.6% | −83.0% |
| Change, 5 years | 88.1% | −97.9% |
| Beta (5Y) | 0.58 | 0.94 |
| Employees | 125 | 142 |
| StockData Score | ||
| Total score | 6 (better) | 4 |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 943× | 2.4× (better) |
| P/B | 24.4× | 0.3× (better) |
| FCF yield | −5.3% (better) | −888% |
| Fair value | – | $0.857 |
| Margin of safety | – | 78.3% |
| Growth | ||
| Revenue growth (TTM) | −31.6% (better) | −38.4% |
| Revenue growth, 5Y average | −13.0% | 56.9% (better) |
| Profitability | ||
| Operating margin | −5432% | −2247% (better) |
| Net margin | −5405% | −2219% (better) |
| FCF margin | −4998% | −2153% (better) |
| Return on equity | −206% | −126% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.87 (better) |
| Interest coverage | – | −40.7× |
| Current ratio | 3.24 (better) | 2.03 |
| Altman Z-score | 27.93 (better) | −8.19 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 6.8% | 53.5% |
| Held by insiders | 12.1% | 32.8% |
| Insider net buying, 12 months | −$15.5M | $146K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | – | 4.4% |
Go deeper
- DBVT stock overview
- DBVT income statement
- DBVT valuation and score
- TCRX stock overview
- TCRX income statement
- TCRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.